Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 1:48 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 817–840 of 8,615 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Infectious Disorder Clear all
Completed Phase 1 Interventional Results available

Evaluating the Safety, Pharmacokinetics, and Antiviral Activity of a Human Monoclonal Antibody (VRC01) in HIV-Infected Adults Undergoing a Brief Treatment Interruption

NCT02463227
View directory record Official record
Conditions
HIV Infections
Interventions
VRC01
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
Birmingham, Alabama • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 19, 2021 · Synced Oct 27, 2026, 1:48 AM EDT
Completed Phase 2 Interventional

A Study of RO5024048 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C, Genotype 1 or 4

NCT00869661
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
Copegus, Pegasys, RO5024048
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 65 Years
Enrollment
413 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2012
U.S. locations
21
States / cities
Birmingham, Alabama • La Jolla, California • Sacramento, California + 18 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 27, 2026, 1:48 AM EDT
Recruiting Phase 2 Interventional

Evaluating the Efficacy and Safety of Saline Irrigation as an Add-On Therapy for Retained Pleural Infections [LYTICS +]

NCT06713382
View directory record Official record
Conditions
Pleural Effusion Associated With Pulmonary Infection, Pleural Effusion Disorder, Pleural Effusions
Interventions
Pleural Saline Irrigation
Combination Product
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 27, 2026, 1:48 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Interaction Oral Contraceptive Pill (OCP)

NCT01063023
View directory record Official record
Conditions
Hepatitis C Virus
Interventions
Ortho Tri-Cyclen®, BMS-650032
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 25, 2011 · Synced Oct 27, 2026, 1:48 AM EDT
Completed Phase 2 Interventional Results available

Phase 2a Study of CG400549 for the Treatment of cABSSSI Caused by Methicillin-resistant Staphylococcus Aureus

NCT01593761
View directory record Official record
Conditions
Skin Infection
Interventions
CG400549
Drug
Lead sponsor
CrystalGenomics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
La Mesa, California
Source: ClinicalTrials.gov public record
Updated Sep 10, 2022 · Synced Oct 27, 2026, 1:48 AM EDT
Completed Not applicable Interventional Results available

SARS-CoV-2 and Influenza A/B in Point-of-Care and Non-Laboratory Settings

NCT06191393
View directory record Official record
Conditions
SARS-CoV-2 Infection, Influenza A, Influenza B
Interventions
Aptitude Medical Systems Metrix COVID/Flu Test
Diagnostic Test
Lead sponsor
Aptitude Medical Systems
Industry
Eligibility
2 Years and older
Enrollment
614 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
3
States / cities
Trussville, Alabama • Goleta, California • Chelmsford, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 13, 2025 · Synced Oct 27, 2026, 1:48 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of HIV-1 Infected Subjects

NCT00098306
View directory record Official record
Conditions
HIV Infections
Interventions
Maraviroc (UK-427,857), Optimized Background Therapy, Placebo
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
16 Years and older
Enrollment
601 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
20
States / cities
Sacramento, California • San Francisco, California • Auroa, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2012 · Synced Oct 27, 2026, 1:48 AM EDT
Completed No phase listed Observational

The Johns Hopkins Transplant Infectious Diseases Prospective Cohort Study

NCT01986504
View directory record Official record
Conditions
Transplantation
Interventions
Not listed
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 100 Years
Enrollment
1,058 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 19, 2016 · Synced Oct 27, 2026, 1:48 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV (vCP205) in HIV-1 Uninfected Adult Volunteers

NCT00001055
View directory record Official record
Conditions
HIV Infections
Interventions
ALVAC-HIV MN120TMG (vCP205), ALVAC-RG Rabies Glycoprotein (vCP65), rgp120/HIV-1 SF-2
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 1997
U.S. locations
6
States / cities
Birmingham, Alabama • Baltimore, Maryland • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 27, 2026, 1:48 AM EDT
Completed Phase 1 Interventional

Underlying Abnormalities in Fat and Muscle Leading to Lipodystrophy Syndrome

NCT00006185
View directory record Official record
Conditions
HIV Infections, Lipodystrophy, Insulin Resistance
Interventions
Avandia administration for 6-12 weeks
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 55 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Mar 2, 2010 · Synced Oct 27, 2026, 1:48 AM EDT
Completed Not applicable Interventional Results available

Symptom Management Efficacy Study to Reduce Distal Neuropathic Pain

NCT03855111
View directory record Official record
Conditions
Neuropathic Pain, HIV Neuropathy, HIV/AIDS, Pain
Interventions
Standard Acupuncture / Moxibustion, Individualized (Tailored) Active Acupuncture / Moxibustion
Other
Lead sponsor
New York University
Other
Eligibility
18 Years and older
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 27, 2026, 1:48 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Reducing Intraoperative Infection Transmission in the Pediatric Operating Room

NCT03992209
View directory record Official record
Conditions
Health Care Associated Infection, Hand Hygiene
Interventions
Standard care, Protocolized care
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
1 Year to 18 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 21, 2022 · Synced Oct 27, 2026, 1:48 AM EDT
Completed Phase 3 Interventional

Rollover Study for Zerit (Stavudine) ER Studies (-096, -099)

NCT00116298
View directory record Official record
Conditions
HIV Infections, AIDS
Interventions
stavudine, efavirenz, lamivudine
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
Not listed
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
19
States / cities
Berkeley, California • Los Angeles, California • West Hollywood, California + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2011 · Synced Oct 27, 2026, 1:48 AM EDT
Completed No phase listed Observational

Comparing Expectorated and Induced Sputum and Pharyngeal Swabs for Cultures, AFB Smears, and Cytokines in Pulmonary Nontuberculous Mycobacterial Infection

NCT01150721
View directory record Official record
Conditions
Mycobacterium Infections, Non-tuberculous
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 80 Years
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 27, 2026, 1:48 AM EDT
Completed No phase listed Observational

Biologic Basis of Liver Cancer From Chronic Hepatitis B

NCT03300414
View directory record Official record
Conditions
Hepatocellular Carcinoma, Hepatitis B, Chronic
Interventions
One time blood draw
Other
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Apr 11, 2019 · Synced Oct 27, 2026, 1:48 AM EDT
Completed Phase 1 Interventional

A Study of Ritonavir (an Anti-HIV Drug) in HIV-Positive Infants and Children

NCT00000952
View directory record Official record
Conditions
HIV Infections
Interventions
Ritonavir, Lamivudine, Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Month to 2 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2004
U.S. locations
12
States / cities
Long Beach, California • San Diego, California • Washington D.C., District of Columbia + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Oct 27, 2026, 1:48 AM EDT
Completed Not applicable Interventional

The Efficacy and Safety of Retrovir in Patients Infected With HIV Who Are Asymptomatic (CDC Group II) or Have Persistent Generalized Lymphadenopathy (CDC Group III)

NCT00002048
View directory record Official record
Conditions
Lymphatic Disease, HIV Infections
Interventions
Zidovudine
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
13 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
22
States / cities
La Jolla, California • San Diego, California • Washington D.C., District of Columbia + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 27, 2026, 1:48 AM EDT
Completed Not applicable Interventional

The COPE Study: Pilot Intervention to Improve Symptom Self-management and Coping in Adults With Post COVID-19

NCT05658536
View directory record Official record
Conditions
Post COVID-19 Condition, Post-COVID-19 Syndrome
Interventions
6-Week Self-Management Group
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 29, 2024 · Synced Oct 27, 2026, 1:48 AM EDT
Completed Not applicable Interventional Results available

Coaching for HCV and HIV

NCT04314414
View directory record Official record
Conditions
Hepatitis C, HIV Infections, Opioid-use Disorder
Interventions
PRC brief motivational interview intervention, Phone contact
Other
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 19, 2022 · Synced Oct 27, 2026, 1:48 AM EDT
Completed Phase 2 Interventional

A Phase II, Stratified, Randomized, Double-Blind, Multi-Center Study of the Safety and Efficacy of Adefovir Dipivoxil (ADF) at Two Dose Levels in Triple Combination Therapies With Protease Inhibitors (PI) and Nucleoside Reverse Transcriptase Inhibitors (RTI) for the Treatment of HIV-Infected Patient

NCT00002184
View directory record Official record
Conditions
HIV Infections
Interventions
Nelfinavir mesylate, Levocarnitine, Adefovir dipivoxil, Saquinavir, Lamivudine, Stavudine, Zidovudine
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
16 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
13
States / cities
Phoenix, Arizona • Los Angeles, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 27, 2026, 1:48 AM EDT
Active, not recruiting Phase 2 Interventional

VIR-2218 and Peginterferon Alfa-2a for Chronic Hepatitis B

NCT06092333
View directory record Official record
Conditions
Chronic Hepatitis B
Interventions
VIR-2218 and peginterferon alfa-2a
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 27, 2026, 1:48 AM EDT
Completed Not applicable Interventional

Multidisciplinary Inpatient Palliative Care Intervention

NCT00325611
View directory record Official record
Conditions
Cerebrovascular Accident, Cancer, Coronary Arteriosclerosis, Heart Failure, Congestive, Diabetes Mellitus, Acquired Immunodeficiency Syndrome, Failure to Thrive, Pulmonary Disease, Chronic Obstructive, Dementia, Kidney Failure, Chronic, Pneumonia, Liver Failure, Renal Failure, Respiratory Failure, Stroke
Interventions
Multidisciplinary palliative care team met with patient
Behavioral
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 15, 2006 · Synced Oct 27, 2026, 1:48 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Long-Acting Progestin Contraception and the Vaginal Microbiome

NCT02740998
View directory record Official record
Conditions
Sexually Transmitted Infection
Interventions
Not listed
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
2
States / cities
Boston, Massachusetts • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jul 17, 2018 · Synced Oct 27, 2026, 1:48 AM EDT
Completed Phase 3 Interventional Results available

Cross-linking for Corneal Ulcers Treatment Trial

NCT02570321
View directory record Official record
Conditions
Corneal Ulcer, Infectious Keratitis, Bacterial Ulcer, Fungal Ulcer
Interventions
Corneal Cross-linking, Anti Fungal Drug
Procedure · Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 18, 2025 · Synced Oct 27, 2026, 1:48 AM EDT